Trial · NCT01987765
Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea
NCT01987765, Completed, Allergan; results first posted 2014-04-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea. Trials, record NCT01987765. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01987765
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea
- NCT number
- NCT01987765
- Status
- Completed
- Enrollment
- 847 participants, actual
- Lead sponsor
- Allergan
- Conditions
- Conjunctivitis, Allergic
- Interventions
- Relestat Ophthalmic Solution 0.05%
- First posted
- 2013-11-19
- Last updated
- 2014-04-29
- Results first posted
- 2014-04-29
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Patients Reporting Adverse Events | Up to 10 Months | An adverse event is any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. |
| Primary | Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale | Baseline, 2 Weeks | Itchiness, conjunctival hyperaemia (redness), lacrimation (tearing), and foreign body sensation were each evaluated on a 4-point scale ranging from 0 (best) to 3 (worst). The eye symptom total score is the sum of the individual symptom scores and ranges from 0 (best) to 12 (worst). A negative number change from baseline indicates an improvement. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Patients Reporting Adverse Events | Up to 10 Months | Safety Assessment Population: included all patients who completed the study. | Percentage of Patients | NUMBER |
| PRIMARY | Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale | Baseline, 2 Weeks | Efficacy Assessment Population: included all patients in the Safety Assessment Population whose data was available for analysis. | Scores on a Scale | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients Reporting Adverse Events | Relestat Ophthalmic Solution 0.05% | 0.13 | Percentage of Patients | ||
| Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale | Relestat Ophthalmic Solution 0.05% | Baseline | 5.58 | Standard Deviation 2.25 | Scores on a Scale |
| Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale | Relestat Ophthalmic Solution 0.05% | Change from Baseline at 2 Weeks | -4.06 | Standard Deviation 2.17 | Scores on a Scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Relestat Ophthalmic Solution 0.05% | 847 | |
| Overall Study | COMPLETED | Relestat Ophthalmic Solution 0.05% | 745 | |
| Overall Study | NOT COMPLETED | Relestat Ophthalmic Solution 0.05% | 102 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Relestat Ophthalmic Solution 0.05% | ||
| Total, other adverse events | Relestat Ophthalmic Solution 0.05% | 0 | 745 |
| Total, serious adverse events | Relestat Ophthalmic Solution 0.05% | 0 | 745 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01987765
GET https://conductscience.org/api/trials/v1/NCT01987765/registered